January 2017 Newsletter

January 23, 2017:

2016 in Review: Ophthalmology Attracts $7.1 Billion in Investments

Johnson & Johnson’s $4.3 billion purchase of Abbott Medical Optics led 58 transactions.

January 23, 2017:

LENSAR Restructured in Wake of Demise of Alphaeon Ophthalmic Business

The femtosecond laser maker said it would continue operations without interruption.

January 23, 2017:

Novartis to Acquire Encore Vision, Developer of Presbyopia Eye Drop

The drug candidate is designed to reverse the gradual stiffening of the crystalline lens that occurs as individuals age.

January 23, 2017:

Roche Purchases ForSight VISION4, Developer of Port Delivery System

The technology is being evaluated for its ability to reduce the burden associated with intraocular injection of anti-VEGF drugs.

January 23, 2017:

Valeant Reveals New Name, Timeline for Vesneo Glaucoma Candidate

CEO said the company planned to resubmit an NDA to the US FDA in Q1-2017.

January 23, 2017:

2016 in Review: Shire’s Xiidra Expands Dry Eye Products Segment with Strong US Launch

Xiidra was made available in late August, and Shire reported Q3-2016 sales of $14 million.

January 23, 2017:

2016 in Review: Zeiss’ SMILE Procedure Gets US FDA Nod As Treatment for Myopia

The firm reported in September that the procedure was available in 61 countries.

January 23, 2017:

2016 in Review: US FDA Approves Ophthalmic Drugs and Devices at Swift Pace

Products that got the nod included the Abbott Symfony extended depth of field lens, Alcon CyPass Micro-Stent, and Allergan/AqueSys XEN Gel Stent.

January 23, 2017:

2016 in Review: Fovista’s Failure in Phase III Study Leads List of Disappointments

Developer Ophthotech raised $740 million to advance the anti-PDGF agent.

January 23, 2017:

2016 in Review: Two MIGS Devices Gain US Approval; Surgeon Use of Technology Soars

Glaukos iStents surgeries exceeded filtration surgeries in the US for the second year in a row.

January 23, 2017:

2016 in Review: IOL Market Shows Modest Growth, Driven by Premium IOLs

Premium lenses accounted for nearly a third of revenues because of significantly higher prices.

January 23, 2017:

2016 in Review: Europe Raises Regulatory Burden for Device Makers

New standards require more postmarket surveillance and sharing of information.

January 23, 2017:

2016 in Review: India Fosters Competitive Market for Anti-VEGF Drugs

Six events combined to increase options, lower prices for retinal patients.

January 23, 2017:

2016 in Review: China Transforms Regulatory Landscape for Drugs, Devices

Companies withdrew 83 percent of the applications awaiting action by the CFDA.

January 23, 2017:

2017 Preview: Potentially Disruptive Products Poised to Reach Ophthalmic Market

Treatments to watch include glaucoma drugs, automated capsulotomy devices, and a nasal neurostimulator.

January 23, 2017:

Market Report: Demand for Disposable Designs will Fuel Surgical Instruments Market

Global revenues in the segment are expected to exceed $1.2 billion in 2017.

January 23, 2017:

White House Scraps Plans for New Medicare Payment Model

The proposal would have paid doctors a 2.5 percent add-on fee for drugs, plus a flat fee of $16.80 per day.

January 23, 2017:

3D-Micromac, Allotex Team Up on Laser to Create ‘Living Contact Lens’

The companies have set an aggressive timeline, planning a commercial rollout in 2018.

January 23, 2017:

US FDA Approves Lucentis for Treatment of Myopic Choroidal Neovascularization

This is the fifth FDA-approved indication for the anti-VEGF agent.

January 23, 2017:

US FDA Expands Labeling for Abbott’s Star S4 and iDESIGN System

The system now can be used for LASIK patients with mixed astigmatism.

January 23, 2017:

January 2017 News Briefs

Social media